Vaccine maker Adimmune Corp (國光生技) last week applied to the Food and Drug Administration (FDA) to run phase I human clinical trials of one of its COVID-19 vaccine candidates, the company said on Monday.
Last month, in the first stage of animal testing, one antigen prototype — four were designed to fight the virus based on the company’s recombinant protein technology — was found to inhibit growth of the novel coronavirus, the company said.
Although the candidate has yet to undergo full animal testing, Adimmune applied to use it in human trials under the FDA’s fast-track program for emergency use authorizations, which is intended to speed up the development of a treatment for COVID-19, it said.
The first stage of animal testing aimed to find out if mice injected with the antigen could generate antibodies strong enough to curb viral replication, while the second stage of testing aims to determine if the antigen would endanger the mice, Adimmune spokesman Pan Fei (潘飛) told the Taipei Times by telephone.
“The second stage will take six months and we just began the testing last month, so it would be too late if we waited for the outcome before moving on to human trials,” Pan added.
Adimmune hopes to start phase I human clinical trials by August, Pan said, adding that about 100 healthy volunteers are to be injected with the vaccine to see if the antigen is safe.
The protocol has not been finalized and must be approved by the FDA, he said.
The company had discussions with the regulator before submitting the application, but does not know how long the regulator’s review might take, Pan added.
If the phase I trials go smoothly, Adimmune plans to apply to run phase II human clinical trials by the end of this year, Pan said.
“We need to test the vaccine candidate’s effectiveness in double-blind phase II clinical trials. We would inject the antigen into volunteers and see if they can be infected in an environment exposed to the novel coronavirus,” he added.
However, as the outbreak is easing in Taiwan, phase II trials might need to be conducted in other countries, Pan said, adding that the firm would discuss the matter with foreign regulators.
The demise of the coal industry left the US’ Appalachian region in tatters, with lost jobs, spoiled water and countless kilometers of abandoned underground mines. Now entrepreneurs are eyeing the rural region with ambitious visions to rebuild its economy by converting old mines into solar power systems and data centers that could help fuel the increasing power demands of the artificial intelligence (AI) boom. One such project is underway by a non-profit team calling itself Energy DELTA (Discovery, Education, Learning and Technology Accelerator) Lab, which is looking to develop energy sources on about 26,305 hectares of old coal land in
Taiwan’s exports soared 56 percent year-on-year to an all-time high of US$64.05 billion last month, propelled by surging global demand for artificial intelligence (AI), high-performance computing and cloud service infrastructure, the Ministry of Finance said yesterday. Department of Statistics Director-General Beatrice Tsai (蔡美娜) called the figure an unexpected upside surprise, citing a wave of technology orders from overseas customers alongside the usual year-end shopping season for technology products. Growth is likely to remain strong this month, she said, projecting a 40 percent to 45 percent expansion on an annual basis. The outperformance could prompt the Directorate-General of Budget, Accounting and
Netflix on Friday faced fierce criticism over its blockbuster deal to acquire Warner Bros Discovery. The streaming giant is already viewed as a pariah in some Hollywood circles, largely due to its reluctance to release content in theaters and its disruption of traditional industry practices. As Netflix emerged as the likely winning bidder for Warner Bros — the studio behind Casablanca, the Harry Potter movies and Friends — Hollywood’s elite launched an aggressive campaign against the acquisition. Titanic director James Cameron called the buyout a “disaster,” while a group of prominent producers are lobbying US Congress to oppose the deal,
Two Chinese chipmakers are attracting strong retail investor demand, buoyed by industry peer Moore Threads Technology Co’s (摩爾線程) stellar debut. The retail portion of MetaX Integrated Circuits (Shanghai) Co’s (上海沐曦) upcoming initial public offering (IPO) was 2,986 times oversubscribed on Friday, according to a filing. Meanwhile, Beijing Onmicro Electronics Co (北京昂瑞微), which makes radio frequency chips, was 2,899 times oversubscribed on Friday, its filing showed. The bids coincided with Moore Threads’ trading debut, which surged 425 percent on Friday after raising 8 billion yuan (US$1.13 billion) on bets that the company could emerge as a viable local competitor to Nvidia
RSS